<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37019821</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2055-6845</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>European heart journal. Cardiovascular pharmacotherapy</Title><ISOAbbreviation>Eur Heart J Cardiovasc Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy.</ArticleTitle><Pagination><StartPage>371</StartPage><EndPage>386</EndPage><MedlinePgn>371-386</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjcvp/pvad025</ELocationID><Abstract><AbstractText Label="BACKGROUND">In post-coronavirus disease-19 (post-COVID-19) conditions (long COVID), systemic vascular dysfunction is implicated, but the mechanisms are uncertain, and the treatment is imprecise.</AbstractText><AbstractText Label="METHODS AND RESULTS">Patients convalescing after hospitalization for COVID-19 and risk factor matched controls underwent multisystem phenotyping using blood biomarkers, cardiorenal and pulmonary imaging, and gluteal subcutaneous biopsy (NCT04403607). Small resistance arteries were isolated and examined using wire myography, histopathology, immunohistochemistry, and spatial transcriptomics. Endothelium-independent (sodium nitroprusside) and -dependent (acetylcholine) vasorelaxation and vasoconstriction to the thromboxane A2 receptor agonist, U46619, and endothelin-1 (ET-1) in the presence or absence of a RhoA/Rho-kinase inhibitor (fasudil), were investigated. Thirty-seven patients, including 27 (mean age 57 years, 48% women, 41% cardiovascular disease) 3 months post-COVID-19 and 10 controls (mean age 57 years, 20% women, 30% cardiovascular disease), were included. Compared with control responses, U46619-induced constriction was increased (P&#xa0;=&#xa0;0.002) and endothelium-independent vasorelaxation was reduced in arteries from COVID-19 patients (P&#xa0;&lt;&#xa0;0.001). This difference was abolished by fasudil. Histopathology revealed greater collagen abundance in COVID-19 arteries {Masson's trichrome (MT) 69.7% [95% confidence interval (CI): 67.8-71.7]; picrosirius red 68.6% [95% CI: 64.4-72.8]} vs. controls [MT 64.9% (95% CI: 59.4-70.3) (P&#xa0;=&#xa0;0.028); picrosirius red 60.1% (95% CI: 55.4-64.8), (P&#xa0;=&#xa0;0.029)]. Greater phosphorylated myosin light chain antibody-positive staining in vascular smooth muscle cells was observed in COVID-19 arteries (40.1%; 95% CI: 30.9-49.3) vs. controls (10.0%; 95% CI: 4.4-15.6) (P&#xa0;&lt;&#xa0;0.001). In proof-of-concept studies, gene pathways associated with extracellular matrix alteration, proteoglycan synthesis, and viral mRNA replication appeared to be upregulated.</AbstractText><AbstractText Label="CONCLUSION">Patients with post-COVID-19 conditions have enhanced vascular fibrosis and myosin light change phosphorylation. Rho-kinase activation represents a novel therapeutic target for clinical trials.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sykes</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-1010-5474</Identifier><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neves</LastName><ForeName>Karla B</ForeName><Initials>KB</Initials><Identifier Source="ORCID">0000-0001-5158-9263</Identifier><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves-Lopes</LastName><ForeName>Rh&#xe9;ure</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caputo</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-3885-7256</Identifier><AffiliationInfo><Affiliation>Universit&#xe0; degli Studi di Padova, 35122 Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Research Facility, Queen Elizabeth University Hospital, NHS Greater Glasgow &amp; Clyde Health Board, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamieson</LastName><ForeName>Nigel B</ForeName><Initials>NB</Initials><Identifier Source="ORCID">0000-0002-9552-4725</Identifier><AffiliationInfo><Affiliation>Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamdar</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9194-547X</Identifier><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legrini</LastName><ForeName>Assya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5377-3048</Identifier><AffiliationInfo><Affiliation>Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leslie</LastName><ForeName>Holly</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntosh</LastName><ForeName>Alasdair</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2534-8647</Identifier><AffiliationInfo><Affiliation>Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McConnachie</LastName><ForeName>Alex</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7262-7000</Identifier><AffiliationInfo><Affiliation>Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrow</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4067-8249</Identifier><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McFarlane</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0002-5325-2872</Identifier><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangion</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3505-7440</Identifier><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Health Board, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAbney</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biomedical and Life Sciences (FBLS), University of Glasgow, Glasgow G12 8QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montezano</LastName><ForeName>Augusto C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-8658-7994</Identifier><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, QC H4A 3J1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touyz</LastName><ForeName>Rhian M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0003-0670-0887</Identifier><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, QC H4A 3J1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Colin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4547-8636</Identifier><AffiliationInfo><Affiliation>Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Health, University of Glasgow, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Health Board, Glasgow, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04403607</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>RE/13/5/30177</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>PG/19/28/34310</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>COV/GLA/20/05</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>PG/17/25/32884</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>CH/12/4/29762</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>COV/LTE/20/10</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RE/18/6/34217</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S018905/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Cardiovasc Pharmacother</MedlineTA><NlmUniqueID>101669491</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1294D5G72N</RegistryNumber><NameOfSubstance UI="C009798">C.I. direct red 80</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>76898-47-0</RegistryNumber><NameOfSubstance UI="D019796">15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q0CH43PGXS</RegistryNumber><NameOfSubstance UI="C049347">fasudil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054460" MajorTopicYN="N">rho-Associated Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019796" MajorTopicYN="N">15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Calcium signalling</Keyword><Keyword MajorTopicYN="N">Endothelium-independent dysfunction</Keyword><Keyword MajorTopicYN="N">Rho-kinase</Keyword><Keyword MajorTopicYN="N">Smooth muscle cells</Keyword><Keyword MajorTopicYN="N">Vascular dysfunction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>22</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37019821</ArticleId><ArticleId IdType="pmc">PMC10236521</ArticleId><ArticleId IdType="doi">10.1093/ehjcvp/pvad025</ArticleId><ArticleId IdType="pii">7109259</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Burden of Disease Long COVID Collaborators ; Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, Blyuss O, Bobkova P, Bonsel G, Borzakova S, Buonsenso D, Butnaru D, Carter A, Chu H, De Rose C, Diab MM, Ekbom E, El Tantawi M, Fomin V, Frithiof R, Gamirova A, Glybochko PV, Haagsma JA, Haghjooy Javanmard S, Hamilton EB, Harris G, Heijenbrok-Kal MH, Helbok R, Hellemons ME, Hillus D, Huijts SM, Hultstr&#xf6;m M, Jassat W, Kurth F, Larsson IM, Lipcsey M, Liu C, Loflin CD, Malinovschi A, Mao W, Mazankova L, McCulloch D, Menges D, Mohammadifard N, Munblit D, Nekliudov NA, Ogbuoji O, Osmanov IM, Pe&#xf1;alvo JL, Petersen MS, Puhan MA, Rahman M, Rass V, Reinig N, Ribbers GM, Ricchiuto A, Rubertsson S, Samitova E, Sarrafzadegan N, Shikhaleva A, Simpson KE, Sinatti D, Soriano JB, Spiridonova E, Steinbeis F, Svistunov AA, Valentini P, van de Water BJ, van den Berg-Emons R, Wallin E, Witzenrath M, Wu Y, Xu H, Zoller T, Adolph C, Albright J, Amlag JO, Aravkin AY, Bang-Jensen BL, Bisignano C, Castellano R, Castro E, Chakrabarti S, Collins JK, Dai X, Daoud F, Dapper C, Deen A, Duncan BB, Erickson M, Ewald SB, Ferrari AJ, Flaxman AD, Fullman N, Gamkrelidze A, Giles JR, Guo G, Hay SI, He J, Helak M, Hulland EN, Kereselidze M, Krohn KJ, Lazzar-Atwood A, Lindstrom A, Lozano R, Malta DC, M&#xe5;nsson J, Mantilla Herrera AM, Mokdad AH, Monasta L, Nomura S, Pasovic M, Pigott DM, Reiner RC Jr, Reinke G, Ribeiro ALP, Santomauro DF, Sholokhov A, Spurlock EE, Walcott R, Walker A, Wiysonge CS, Zheng P, Bettger JP, Murray CJL, Vos T. Estimated Global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022;328:1604&#x2013;1615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen EL, Go&#xdf;ling A, Adam G, Aepfelbacher M, Behrendt CA, Cavus E, Cheng B, Fischer N, Gallinat J, K&#xfc;hn S, Gerloff C, Koch-Gromus U, H&#xe4;rter M, Hanning U, Huber TB, Kluge S, Knobloch JK, Kuta P, Schmidt-Lauber C, L&#xfc;tgehetmann M, Magnussen C, Mayer C, Muellerleile K, M&#xfc;nch J, N&#xe4;gele FL, Petersen M, Renn&#xe9; T, Riedl KA, Rimmele DL, Sch&#xe4;fer I, Schulz H, Tahir E, Waschki B, Wenzel JP, Zeller T, Ziegler A, Thomalla G, Twerenbold R, Blankenberg S.. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: the Hamburg City Health Study COVID programme. Eur Heart J 2022;43:1124&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755397</ArticleId><ArticleId IdType="pubmed">34999762</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, Dasmari&#xf1;as MC, Jubilo KG, Samranvedhya J, Lipsitch M, Cohen K.. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 2021:n1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow AJ, Sykes R, McIntosh A, Kamdar A, Bagot C, Bayes HK, Blyth KG, Briscoe M, Bulluck H, Carrick D, Church C, Corcoran D, Findlay I, Gibson VB, Gillespie L, Grieve D, Hall Barrientos P, Ho A, Lang NN, Lennie V, Lowe DJ, Macfarlane PW, Mark PB, Mayne KJ, McConnachie A, McGeoch R, McGinley C, McKee C, Nordin S, Payne A, Rankin AJ, Robertson KE, Roditi G, Ryan N, Sattar N, Allwood-Spiers S, Stobo D, Touyz RM, Veldtman G, Watkins S, Weeden S, Weir RA, Welsh P, Wereski R, CISCO-19 Consortium , Basu N, Brown A, Butler E, Dobbin SJH, Dougherty A, Dymock L, Fallon K, Gilmour L, Hopkins T, Lees JS, McInnes IB, McLennan E, Savage F, Siebert S, Tynan N, Woodward R, Mangion K, Berry C. A multisystem, cardio-renal investigation of post-COVID-19 illness. Nat Med 2022;28:1303&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9205780</ArticleId><ArticleId IdType="pubmed">35606551</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Gonz&#xe1;lez A, Ara&#xfa;jo-Ameijeiras A, Fern&#xe1;ndez-Villar A, Crespo M, Poveda E.. Long COVID in hospitalized and non-hospitalized patients in a large cohort in Northwest Spain, a prospective cohort study. Sci Rep 2022;12:3369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8888560</ArticleId><ArticleId IdType="pubmed">35233035</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, L&#xfc;scher T.. COVID-19 is, in the end, an endothelial disease. Eur Heart J 2020;41:3038&#x2013;3044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseau AF, Minguet P, Colson C, Kellens I, Chaabane S, Delanaye P, Cavalier E, Chase JG, Lambermont B, Misset B.. Post-intensive care syndrome after a critical COVID-19: cohort study from a Belgian follow-up clinic. Ann Intensive Care. 2021;11:118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319705</ArticleId><ArticleId IdType="pubmed">34324073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, M&#xfc;ller MA, Drosten C, P&#xf6;hlmann S.. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181:271&#x2013;280.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H.. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigrahi S, Goswami T, Ferrari B, Antonelli CJ, Bazdar DA, Gilmore H, Freeman ML, Lederman MM, Sieg SF.. SARS-CoV-2 spike protein destabilizes microvascular homeostasis. Microbiol Spectr 2021;9:e0073521. doi: 10.1128/Spectrum.00735-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00735-21</ArticleId><ArticleId IdType="pmc">PMC8693925</ArticleId><ArticleId IdType="pubmed">34935423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner JUG, Bojkova D, Shumliakivska M, Lux&#xe1;n G, Nicin L, Aslan GS, Milting H, Kandler JD, Dendorfer A, Heumueller AW, Fleming I, Bibli SI, Jakobi T, Dieterich C, Zeiher AM, Ciesek S, Cinatl J, Dimmeler S.. Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants. Basic Res Cardiol 2021;116:42. doi: 10.1007/s00395-021-00882-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00395-021-00882-8</ArticleId><ArticleId IdType="pmc">PMC8256413</ArticleId><ArticleId IdType="pubmed">34224022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y, Zhang J, Schiavon CR, He M, Chen L, Shen H, Zhang Y, Yin Q, Cho Y, Andrade L, Shadel GS, Hepokoski M, Lei T, Wang H, Zhang J, Yuan JXJ, Malhotra A, Manor U, Wang S, Yuan ZY, Shyy JYJ.. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res 2021;128:1323&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091897</ArticleId><ArticleId IdType="pubmed">33784827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, Englert H, Byrne M, Bergin C, O'Sullivan JM, Martin-Loeches I, Nadarajan P, Bannan C, Mallon PW, Curley GF, Preston RJS, Rehill AM, McGonagle D, Ni Cheallaigh C, Baker RI, Renn&#xe9; T, Ward SE, O'Donnell JS; Irish COVID-19 Vasculopathy Study (iCVS) investigators . Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost 2021;19:2546&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockton RA, Shenkar R, Awad IA, Ginsberg MH.. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med 2010;207:881&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856024</ArticleId><ArticleId IdType="pubmed">20308363</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato M, Tani E, Fujikawa H, Kaibuchi K. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 2000;87:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">10926869</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik M, Kapur M, Gupta V, Sethi H, Srivastava K. Ripasudil endgame: role of Rho-kinase inhibitor as a last-ditch-stand towards maximally tolerated medical therapy to a patient of advanced glaucoma. Clin Ophthalmol 2021;15:2683&#x2013;2692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238538</ArticleId><ArticleId IdType="pubmed">34194222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonkar C, Doharey PK, Rathore AS, Singh V, Kashyap D, Sahoo AK, Mittal N, Sharma B, Jha HC.. Repurposing of gastric cancer drugs against COVID-19. Comput Biol Med 2021;137:104826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420180</ArticleId><ArticleId IdType="pubmed">34537409</ArticleId></ArticleIdList></Reference><Reference><Citation>Cal&#xf2; LA, Bertoldi G, Davis PA. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: support from Bartter's and Gitelman's syndrome patients. Pharmacol Res 2020;158:104903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217778</ArticleId><ArticleId IdType="pubmed">32430287</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedi F, Rezaee R, Karimi G. Plausibility of therapeutic effects of Rho kinase inhibitors against severe acute respiratory syndrome coronavirus 2 (COVID-19). Pharmacol Res 2020;156:104808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195000</ArticleId><ArticleId IdType="pubmed">32283223</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangion K, Morrow A, Bagot C, Bayes H, Blyth KG, Church C, Corcoran D, Delles C, Gillespie L, Grieve D, Ho A, Kean S, Lang NN, Lennie V, Lowe DJ, Kellman P, Macfarlane PW, McConnachie A, Roditi G, Sykes R, Touyz RM, Sattar N, Wereski R, Wright S, Berry C. The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus Disease-19 (CISCO-19) study. Cardiovasc Res 2020;116:2185&#x2013;2196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454350</ArticleId><ArticleId IdType="pubmed">32702087</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves-Lopes R, Neves KB, Anagnostopoulou A, Rios FJ, Lacchini S, Montezano AC, Touyz RM.. Crosstalk between vascular redox and calcium signaling in hypertension involves TRPM2 (Transient Receptor Potential Melastatin 2) cation channel. Hypertension 2020;75:139&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">31735084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford TJ, Rocchiccioli P, Good R, McEntegart M, Eteiba H, Watkins S, Shaukat A, Lindsay M, Robertson K, Hood S, Yii E, Sidik N, Harvey A, Montezano AC, Beattie E, Haddow L, Oldroyd KG, Touyz RM, Berry C.. Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J 2018;39:4086&#x2013;4097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6284165</ArticleId><ArticleId IdType="pubmed">30165438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z, Li X, Fan RLY, Yang KY, Ng CSH, Lau RWH, Wong RHL, Ng KK, Wang CC, Ye P, Fu Z, Chin AWH, Lai MYA, Huang Y, Tian XY, Poon LLM, Lui KO.. A human pluripotent stem cell-based model of SARS-CoV-2 infection reveals an ACE2-independent inflammatory activation of vascular endothelial cells through TLR4. Stem Cell Reports 2022;17:538&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8851885</ArticleId><ArticleId IdType="pubmed">35180397</ArticleId></ArticleIdList></Reference><Reference><Citation>McCracken IR, Saginc G, He L, Huseynov A, Daniels A, Fletcher S, Peghaire C, Kalna V, Andaloussi-M&#xe4;e M, Muhl L, Craig NM, Griffiths SJ, Haas JG, Tait-Burkard C, Lendahl U, Birdsey GM, Betsholtz C, Noseda M, Baker AH, Randi AM.. Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells. Circulation 2021;143:865&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7899720</ArticleId><ArticleId IdType="pubmed">33405941</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhl L, He L, Sun Y, M&#xe4;e MA, Pietil&#xe4; R, Liu J, Genov&#xe9; G, Zhang L, Xie Y, Leptidis S, Mocci G, Stritt S, Osman A, Anisimov A, Hemanthakumar KA, R&#xe4;s&#xe4;nen M, Hansson EM, Bj&#xf6;rkegren J, Vanlandewijck M, Blomgren K, M&#xe4;kinen T, Peng XR, Hu Y, Ernfors P, Arnold TD, Alitalo K, Lendahl U, Betsholtz C.. The SARS-CoV-2 receptor ACE2 is expressed in mouse pericytes but not endothelial cells: implications for COVID-19 vascular research. Stem Cell Reports 2022;17:1089&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9022216</ArticleId><ArticleId IdType="pubmed">35452595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandadeva D, Young BE, Stephens BY, Grotle AK, Skow RJ, Middleton AJ, Haseltine FP, Fadel PJ.. Blunted peripheral but not cerebral vasodilator function in young otherwise healthy adults with persistent symptoms following COVID-19. Am J Physiol Heart Circ Physiol 2021;321:H479&#x2013;H484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8384473</ArticleId><ArticleId IdType="pubmed">34296966</ArticleId></ArticleIdList></Reference><Reference><Citation>Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner A, Montezano AC.. Vascular smooth muscle contraction in hypertension. Cardiovasc Res 2018;114:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5852517</ArticleId><ArticleId IdType="pubmed">29394331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson D, Ngai M, Wu R, Hou H, Schoffel AC, Erice C, Mandla S, Billia F, Wilson MD, Radisic M, Fan E, Trahtemberg U, Baker A, McIntosh C, Fan CPS, dos Santos CC, Kain KC, Hanneman K, Thavendiranathan P, Fish JE, Howe KL. Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies. eBioMedicine 2022;78:103982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989492</ArticleId><ArticleId IdType="pubmed">35405523</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom AL. The biosynthesis of factor VIII. Clin Haematol 1979;8:53&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">367666</ArticleId></ArticleIdList></Reference><Reference><Citation>Videm V, Albrigtsen M. Soluble ICAM-1 and VCAM-1 as markers of endothelial activation. Scand J Immunol 2008;67:523&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">18363595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;tt U, Solomon C, Fries D, Bentzer P. The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review. Scand J Trauma Resusc Emerg Med 2016;24:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828893</ArticleId><ArticleId IdType="pubmed">27068016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693329</ArticleId><ArticleId IdType="pubmed">18161745</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishijima Y, Hader SN, Hanson AJ, Zhang DX, Sparapani R, Gutterman DD, Beyer AM.. Prolonged endothelial-dysfunction in human arterioles following infection with SARS-CoV-2. Cardiovasc Res 2022;118:18&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689948</ArticleId><ArticleId IdType="pubmed">34755839</ArticleId></ArticleIdList></Reference><Reference><Citation>Queisser KA, Mellema RA, Middleton EA, Portier I, Manne BK, Denorme F, Beswick EJ, Rondina MT, Campbell RA, Petrey AC.. COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction. JCI Insight 2021;6:147472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492325</ArticleId><ArticleId IdType="pubmed">34314391</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalick L, Weidenfeld S, Grimmer B, Fatykhova D, Solymosi P, Behrens F, Dohmen M, Brack M, Schulz S, Thomasch E, Simmons S, M&#xfc;ller-Redetzky H, Suttorp N, Kurth F, Corman V, Hocke A, Witzenrath M, Hippenstiel S, Kuebler W.. In vitro screening identifies TRPV4 as target for endothelial barrier stabilization in COVID-19. FASEB J 2021;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7651836</ArticleId><ArticleId IdType="pubmed">33154030</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomou E, Souvaliotis N, Lampsas S, Siasos G, Poulakou G, Theofilis P, Papaioannou TG, Haidich AB, Tsaousi G, Ntousopoulos V, Sakka V, Charalambous G, Rapti V, Raftopoulou S, Syrigos K, Tsioufis C, Tousoulis D, Vavuranakis M.. Endothelial dysfunction in acute and long standing COVID-19: a prospective cohort study. Vasc Pharmacol 2022;144:106975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893931</ArticleId><ArticleId IdType="pubmed">35248780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P, Molino A, Calcaterra I, Formisano R, Stufano S, Spedicato GA, Motta A, Papa A, Di Minno MND, Maniscalco M.. Clinical assessment of endothelial function in convalescent COVID-19 patients undergoing multidisciplinary pulmonary rehabilitation. Biomedicines 2021;9:614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8226503</ArticleId><ArticleId IdType="pubmed">34071308</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro L, Falsetti L, Zaccone V, Nesci A, Tosato M, Giupponi B, Savastano MC, Moroncini G, Gasbarrini A, Landi F, Santoliquido A, On Behalf Of Gemelli Against Covid-Post-Acute Care Study Group null. Impaired endothelial function in convalescent phase of COVID-19: a 3 month follow up observational prospective study. J Clin Med 2022;11:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8999944</ArticleId><ArticleId IdType="pubmed">35407382</ArticleId></ArticleIdList></Reference><Reference><Citation>Alley H, Owens CD, Gasper WJ, Grenon SM. Ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery in clinical research. J Vis Exp 2014;22:e52070. doi: 10.3791/52070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4353419</ArticleId><ArticleId IdType="pubmed">25406739</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolfe BE, Worth NF, World CJ, Campbell JH, Campbell GR. Rho and vascular disease. Atherosclerosis 2005;183:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15982657</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki P, Birukov KG. Rho and reactive oxygen species at crossroads of endothelial permeability and inflammation. Antioxid Redox Signal 2019;31:1009&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6765062</ArticleId><ArticleId IdType="pubmed">31126187</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoldi G, Gianesello L, Cal&#xf2; LA. Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVID-19. Aliment Pharmacol Ther 2020;52:577&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404523</ArticleId><ArticleId IdType="pubmed">32656827</ArticleId></ArticleIdList></Reference><Reference><Citation>Cal&#xf2; LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A, Pessina AC. ACE2 and angiotensin 1&#x2013;7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications. J Nephrol 2010;23:472&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">20349406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, Kubota T, Ichiki T, Amano M, Kaibuchi K, Takeshita A.. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 2004;37:537&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">15276023</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolz SS, Vogel L, Sollinger D, Derwand R, de Wit C, Loirand G, Pohl U.. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation 2003;107:3081&#x2013;3087.</Citation><ArticleIdList><ArticleId IdType="pubmed">12796138</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Q, Zhang Y, Chen H, Li J. Rho kinase: a new target for treatment of cerebral ischemia/reperfusion injury. Neural Regen Res 2013;8:1180&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107606</ArticleId><ArticleId IdType="pubmed">25206412</ArticleId></ArticleIdList></Reference><Reference><Citation>Defert O, Boland S. Rho kinase inhibitors: a patent review (2014&#x2013;2016). Expert Opin Ther Pat 2017;27:507&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">28048944</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimokawa H, Sunamura S, Satoh K. RhoA/Rho-kinase in the cardiovascular system. Circ Res 2016;118:352&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">26838319</ArticleId></ArticleIdList></Reference><Reference><Citation>Possa SS, Charafeddine HT, Righetti RF, da Silva PA, Almeida-Reis R, Saraiva-Romanholo BM, Perini A, Prado CM, Leick-Maldonado EA, Martins MA, Tib&#xe9;rio I de FLC. Rho-kinase inhibition attenuates airway responsiveness, inflammation, matrix remodeling, and oxidative stress activation induced by chronic inflammation. Am J Physiol Lung Cell Mol Physiol 2012;303:L939&#x2013;L952.</Citation><ArticleIdList><ArticleId IdType="pubmed">23002076</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>